Canada: Changes To Food And Drugs Act Address Patient Safety - Passage Of Vanessa’s Law

Last Updated: December 12 2014
Article by Kathryn M. Frelick and Lauren Parrish

Bill C-17, the Protecting Canadians from Unsafe Drugs Act (Vanessa's Law) was passed by the federal legislature and received Royal Assent on November 6, 2014. It represents the most substantial amendment to the Food and Drugs Act (Canada) (FDA) in over 50 years and has significant implications for the health industry, including drug and medical device manufacturers and health care institutions.

Vanessa's Law is named after the daughter of Member of Parliament Terence Young, who died after taking a prescription drug that was later found to be unsafe and removed from the market.

Vanessa's Law modernizes the FDA to introduce a "life-cycle" approach to the oversight of therapeutic products, including post-market safety and assessment powers, stronger enforcement mechanisms and harsher penalties. It will require "prescribed" health care institutions, likely hospitals, to report serious adverse drug reactions and medical device incidents to Health Canada. It is also aimed at increasing openness and transparency by making certain information publicly available.

Definitions and Scope

Vanessa's Law introduces three new definitions: "therapeutic product", "therapeutic product authorization" and "confidential business information".

  • Therapeutic product is broadly defined to encompass all drugs, devices or any combination of the two. This includes non-prescription, over-the-counter medicines, vaccines and gene therapies. Natural health products are specifically excluded.
  • Therapeutic product authorization is an authorization that permits the import, sale, advertisement, manufacture, preparation, preservation, packaging, labelling, storing or testing of a therapeutic product. The holder of a therapeutic product authorization is required to comply with any terms or conditions associated with that authorization.
  • Confidential business information means information that is not publicly available, for which reasonable measures have been taken to ensure it is not available to the public, and that has actual or potential economic value to the business or its competitors because it is not publicly available. Its disclosure would result in a material financial loss to the company or a material financial gain to its competitors.

Increased Ministerial Powers

Vanessa's Law regulates a broad range of activities for therapeutic products including:

  • Public disclosure of prescribed information relating to clinical trials and investigational tests by authorization holders. In addition, all orders or regulatory decisions issued by the Minister of Health ("Minister") must be made publicly available.
  • Increased powers of the Minister in relation to the disclosure of confidential business information, packaging/labelling, assessments and testing, and product recalls where associated with risk of harm to human health. For example:
    • Disclosure of Confidential Business Information - where the Minister believes a therapeutic product may present a "serious risk of injury to human health", the Minister may gather and disclose confidential business information with no notice or consent from the affected party.
    • Packaging/Labelling – where necessary to prevent injury to health, the Minister may order the authorization holder to modify or replace a product label or packaging.
    • Recall – the Minister may order a therapeutic product to be recalled where it is deemed to present a serious or imminent risk of injury to health. Alternatively, if corrective action can effectively address the risk, the order may provide for corrective action. This may or may not allow the sale of the therapeutic product, subject to conditions.
    • Product information – subject to regulations, the Minister may order that the authorization holder compile information, conduct assessments, further product testing or studies or monitor experience and supply the information to the Minister. This will allow information on "real world" safety and effectiveness to be collected by Health Canada post-approval.

Mandatory Reporting by Health Care Institutions

Prescribed health care institutions will be required to report serious adverse drug reactions or medical device incidents that involve therapeutic products to Health Canada. It is widely acknowledged that under the current voluntary scheme, adverse reactions are under-reported. The time and difficulty associated with submitting reports and lack of feedback from Health Canada when a report has been submitted can be disincentives to reporting.

New regulations will set out definitions and the specifics of these reporting obligations. In recognition of the additional administrative burden that mandatory reporting will place on health care institutions, the Minister must take into account existing information management systems, such as electronic health record systems, when making recommendations. Health care institutions are also subject to penalties for non-compliance with Vanessa's Law.

Regulation Making Authority

Vanessa's Law provides broad authority for the Governor-in-Council to make regulations with respect to therapeutic products and the issuance of therapeutic product authorizations. This includes regulations relating to post-market assessments, tests and studies, monitoring of experience and information compilation. The regulations may also incorporate documents by reference, for example, policy and guidance documents, technical standards and the like.

Offences and Penalties

Consistent with the approach being taken in other areas, there are new offences and penalties for noncompliance with Vanessa's Law that focus on economic disincentives. On conviction by indictment, potential fines have been increased from $5,000 per day to up to $5 million per day, imprisonment for a term not exceeding two years, or both. The Act gives the court discretion to order even larger fines where a violation of the provisions involves intentional conduct, such as making false or misleading statements to Health Canada or wilful or reckless harm to human health.

Officers and directors may be personally liable for the act of the corporation. Corporate officers, directors, or agents who "direct, authorize, assent to, participate in or otherwise acquiesce in the commission of an offence" are individually liable and subject to penalties, whether or not they are prosecuted for the offence. Importantly, Vanessa's Law provides for a due diligence defence, unless the contravention is intentional.

In Force Dates

Some of the provisions of Vanessa's Law are in force, for example, the power to recall unsafe therapeutic products, to direct label changes or modifications and to impose greater fines and penalties. Other changes will not come into force until supporting regulations have been developed and there will be opportunities for further consultation. From an operational perspective, Health Canada will also need to ensure that the supporting frameworks are in place.


Vanessa's Law reflects a fundamental shift in Canada's approach to patient safety for therapeutic products. Particularly in light of the enhanced penalty provisions, the potential risk for drug and medical device companies and their corporate directors and officers is considerable. Senior management will need to play an active and visible role in fostering a culture of compliance and in overseeing the organization's corporate compliance program.

In addition to understanding the therapeutic product provisions under Vanessa's Law, it is critical that organizations develop and/or update their compliance programs in order to be able to rely on a statutory due diligence defence. As a starting point, organizations should conduct an internal audit of their current compliance programs in relation to the requirements for therapeutic products. This will enable the identification of gaps and the development of a compliance strategy to place the organization in as defensible a position as possible.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Kathryn M. Frelick
In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.